Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis

Clinical and Vaccine Immunology

Volumn 19, Issue 3, 2012, Pages 436-442

  Suzuki, Yuzo ^a   Suda, Takafumi ^a   Asada, Kazuhiro ^b   Miwa, Seiichi ^c   Suzuki, Masako ^a   Fujie, Michio ^a   Furuhashi, Kazuki ^a   Nakamura, Yutaro ^a   Inui, Naoki ^a   Shirai, Toshihiro ^b   Hayakawa, Hiroshi ^c   Nakamura, Hirotoshi ^a   Chida, Kingo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA GENERAL HOSPITAL   (Japan)

^c National Hospital Organization   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; TRYPTOPHAN;

AGED; ALBUMIN BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LEUKOCYTE COUNT; LIQUID CHROMATOGRAPHY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MILIARY TUBERCULOSIS; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY FAILURE; SURVIVAL PREDICTION; THORAX RADIOGRAPHY; TUBERCULOUS PLEURISY; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE; SERUM; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TRYPTOPHAN; TUBERCULOSIS, PULMONARY;

EID: 84863229688     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05402-11     Document Type: Article

References (25)

1. Almeida AS, et al. 2009. Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J. Immunol. 183:718-731.
2. Aluvihare VR, Kallikourdis M, Betz AG. 2004. Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 5:266-271. (Pubitemid 38332123)
3. Bozza S, et al. 2005. A crucial role for tryptophan catabolism at the host/Candida albicans interface. J. Immunol. 174:2910-2918. (Pubitemid 40279709)
4. Brandacher G, et al. 2006. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 12:1144-1151. (Pubitemid 43342502)
5. Hayashi T, et al. 2001. Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase. Infect. Immun. 69:6156-6164. (Pubitemid 32885177)
6. Huttunen R, et al. 2010. High activity of indoleamine 2,3-dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients. Shock 33:149-154.
7. Ino K, et al. 2006. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br. J. Cancer 95:1555-1561. (Pubitemid 44863359)
8. Jung ID, et al. 2009. Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock. J. Immunol. 182:3146-3154.
9. Katz JB, Muller AJ, Prendergast GC. 2008. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev. 222:206-221. (Pubitemid 351430372)
10. Li Q, et al. 2011. Pleural fluid from tuberculous pleurisy inhibits the function of T cells and differentiation of Th1 cells via immunosuppressive factors. Cell. Mol. Immunol. 8:172-180.
11. Mellor AL, Munn DH. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4:762-774. (Pubitemid 39336293)
12. Munn DH, Mellor AL. 2007. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117:1147-1154. (Pubitemid 46718399)
13. Munn DH, et al. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191-1193. (Pubitemid 28406294)
14. Schröcksnadel K, Wirleitner B, Winkler C, Fuchs D. 2006. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim Acta 364:82-90. (Pubitemid 43120630)
15. Suzuki Y, et al. 2011. Serum activity of indoleamine 2,3-dioxygenase predicts prognosis of community-acquired pneumonia. J. Infect. 63:215-222.
16. Suzuki Y, et al. 2010. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67:361-365.
17. Tattevin P, et al. 2010. Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. J. Infect. Dis. 201:956-966.
18. Tuberculosis Surveillance Center RIT JATA. 2011. Tuberculosis annual report 2009. Series 1. Summary of TB notification statistics in 2009. Kekkaku 86:127-130.
19. Uyttenhove C, et al. 2003. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9:1269-1274. (Pubitemid 37279849)
20. Wallis RS, et al. 2010. Biomarkers and diagnosis for tuberculosis: progress, needs, and translation into practice. Lancet 375:1920-1937.
21. Wallis RS, et al. 2009. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect. Dis. 9:162-172.
22. Wang Y, et al. 2010. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat. Med. 16:279-285.
23. Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D. 2007. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214:8-14. (Pubitemid 46032994)
24. WHO. 2008. Global tuberculosis control-surveillance, planning financing. WHO/HTM/TB 2008.393. World Health Organization, Geneva, Switzerland.
25. Zelante T, Fallarino F, Bistoni F, Puccetti P, Romani L. 2009. Indoleamine 2,3 dioxygenase in infection: the paradox of an evasive strategy that benefits the host. Microbes Infect. 11:133-141.